HK1072373A1 - Virus coat protein/receptor chimeras and methods of use - Google Patents

Virus coat protein/receptor chimeras and methods of use

Info

Publication number
HK1072373A1
HK1072373A1 HK05105100.1A HK05105100A HK1072373A1 HK 1072373 A1 HK1072373 A1 HK 1072373A1 HK 05105100 A HK05105100 A HK 05105100A HK 1072373 A1 HK1072373 A1 HK 1072373A1
Authority
HK
Hong Kong
Prior art keywords
methods
coat protein
virus coat
receptor chimeras
chimeras
Prior art date
Application number
HK05105100.1A
Other languages
English (en)
Inventor
Anthony L Devico
Timothy R Fouts
Robert G Tuskan
Original Assignee
Univ Maryland Biotech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland Biotech Inst filed Critical Univ Maryland Biotech Inst
Publication of HK1072373A1 publication Critical patent/HK1072373A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
HK05105100.1A 2001-08-21 2005-06-20 Virus coat protein/receptor chimeras and methods of use HK1072373A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/934,060 US6908612B2 (en) 1999-10-08 2001-08-21 Virus coat protein/receptor chimeras and methods of use
PCT/US2002/026543 WO2003016333A2 (en) 2001-08-21 2002-08-21 Virus coat protein/receptor chimeras and methods of use

Publications (1)

Publication Number Publication Date
HK1072373A1 true HK1072373A1 (en) 2005-08-26

Family

ID=25464900

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05105100.1A HK1072373A1 (en) 2001-08-21 2005-06-20 Virus coat protein/receptor chimeras and methods of use

Country Status (13)

Country Link
US (2) US6908612B2 (ko)
EP (1) EP1425036A4 (ko)
JP (1) JP4500541B2 (ko)
KR (1) KR101001859B1 (ko)
CN (1) CN100463694C (ko)
AU (1) AU2002355966B2 (ko)
BR (1) BR0212093A (ko)
CA (1) CA2457414C (ko)
HK (1) HK1072373A1 (ko)
IL (2) IL160512A0 (ko)
MX (1) MXPA04001585A (ko)
WO (1) WO2003016333A2 (ko)
ZA (1) ZA200402190B (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076636A1 (en) * 1993-05-07 2004-04-22 Ranajit Pal HIV immunogenic complexes
WO2005063282A1 (en) 2003-12-23 2005-07-14 Centocor, Inc. Anti-retroviral agents, compositions, methods and uses
WO2007011827A2 (en) * 2005-07-15 2007-01-25 University Of Maryland Biotechnology Institute G1 cytostatic agents enhancing antiviral activity of viral-envelope targeting drugs and antibodies
EP1754715A1 (de) * 2005-08-19 2007-02-21 Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut Impfstoff auf Basis virusneutralisierender Antikörper
WO2007024976A2 (en) * 2005-08-23 2007-03-01 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
WO2007066236A2 (en) * 2005-11-28 2007-06-14 Institut De La Recherche Pour Le Développement (Ird) Chimeric hiv-1 gp120 glycoproteins and their biological applications
AU2007207544A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
CN101899100B (zh) * 2007-02-02 2013-04-03 同济大学 抗hiv-i的多肽、其编码序列及其用途
US20100189703A1 (en) * 2007-03-26 2010-07-29 Lewis George K Non-destructive method to quantify and isolate antigen-specific b cells and uses thereof
AU2008250953B2 (en) * 2007-05-14 2013-10-31 Vancouver Biotech Ltd. Carbohydrate-containing pan cancer marker
EP2542703A4 (en) * 2010-03-02 2013-10-23 Int Aids Vaccine Initiative NEW HIV-1 ENVELOPE GLYCOPROTEIN
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US8828932B2 (en) 2010-05-03 2014-09-09 New York Blood Center, Inc. Bifunctional molecules for inactivating HIV and blocking HIV entry
EP2691530B1 (en) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10913798B2 (en) * 2015-04-24 2021-02-09 The Regents Of The University Of California Modulators of ROR1-ROR2 binding
JP6987134B2 (ja) * 2016-06-27 2021-12-22 ジュノー セラピューティクス インコーポレイテッド ペプチドエピトープを同定する方法、そのようなエピトープに結合する分子および関連用途
EP3621649A2 (en) * 2017-05-10 2020-03-18 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405914D0 (en) 1994-03-24 1994-05-11 Discovision Ass Video decompression
WO1988001304A1 (en) 1986-08-21 1988-02-25 The Trustees Of Columbia University In The City Of Dna encoding the t cell surface protein t4 and use of fragments of t4 in the treatment of aids
IL83687A (en) 1987-08-30 1995-03-30 Yeda Res & Dev Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositions
ZA89430B (en) 1988-01-22 1989-10-25 Gen Hospital Corp Cloned genes encoding ig-cd4 fusion proteins and the use thereof
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5612205A (en) 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
AU653366B2 (en) 1990-09-28 1994-09-29 Hospital For Joint Diseases Method for inhibiting the infectivity of human immunodeficiency virus
WO1992006990A1 (en) 1990-10-17 1992-04-30 The United States Of America, Represented By The Secretary, United States Department Of Commerce Molecular clones of hiv-1 and uses thereof
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
ATE193208T1 (de) 1992-02-10 2000-06-15 Univ Duke Verwendung synthetischer peptide zur induktion der toleranz gegen t- und b-zell epitope von autoantigenen
US5925741A (en) 1992-12-31 1999-07-20 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding-associated epitopes
WO1994015638A1 (en) 1992-12-31 1994-07-21 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding-associated epitopes
DE69428896T2 (de) 1993-05-07 2002-06-20 Akzo Nobel N.V., Arnheim/Arnhem Hiv immunogene komplexe
WO1994029442A2 (en) 1993-06-14 1994-12-22 Basf Aktiengesellschaft Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5695977A (en) 1995-08-31 1997-12-09 Genetic Information Research Institute Site directed recombination
IL119587A (en) 1996-11-07 2000-12-06 Univ Ramot Method of preparing and for obtaining bimolecular interactions
WO1998047916A1 (en) 1997-04-18 1998-10-29 President And Fellows Of Harvard College Bifunctional polypeptides for cell-specific viral targeting
US6060316A (en) * 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
ES2284532T3 (es) * 1999-10-08 2007-11-16 University Of Maryland Biotechnology Institute Quimeras de proteina de envuelta viral/receptor y metodos de uso.

Also Published As

Publication number Publication date
JP2005503147A (ja) 2005-02-03
JP4500541B2 (ja) 2010-07-14
CA2457414A1 (en) 2003-02-27
US7399473B2 (en) 2008-07-15
US20020155121A1 (en) 2002-10-24
WO2003016333A2 (en) 2003-02-27
AU2002355966B2 (en) 2007-01-18
CN100463694C (zh) 2009-02-25
CA2457414C (en) 2012-08-07
ZA200402190B (en) 2005-07-27
KR101001859B1 (ko) 2010-12-17
IL160512A0 (en) 2004-07-25
WO2003016333A3 (en) 2003-07-31
EP1425036A4 (en) 2007-01-10
US20050221445A1 (en) 2005-10-06
KR20040049841A (ko) 2004-06-12
BR0212093A (pt) 2004-11-30
MXPA04001585A (es) 2005-03-07
US6908612B2 (en) 2005-06-21
IL204302A (en) 2011-04-28
EP1425036A2 (en) 2004-06-09
CN1561229A (zh) 2005-01-05

Similar Documents

Publication Publication Date Title
HK1072373A1 (en) Virus coat protein/receptor chimeras and methods of use
IL157142A0 (en) Modified antibodies and methods of use
EP1501514A4 (en) PROTEIN-KINASE MODULATORS AND METHODS OF USE
AU2002258790A1 (en) Novel microarrays and methods of use thereof
HK1074881A1 (en) Arrays of microparticles and methods of preparation thereof
WO2003059257A8 (en) Anti-angiogenic proteins and fragmentsand methods of use thereof
HK1053673A1 (zh) 使蛋白不穩定的方法及其用途
EP1497654A4 (en) IMMUNOGLOBULIN E VACCINES AND METHODS OF USE
AU2002246808A1 (en) Human nucleic acids and polypeptides and methods of use thereof
HK1154504A1 (en) Chemokine receptor antagonists and methods of use thereof
EP1487864A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THESE POLYPEPTIDES AND METHODS OF USE THEREOF
AU2002351175A8 (en) Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
IL157264A0 (en) Platelet glycoprotein ib alpha fusion polypeptides and methods of use thereof
AU2002251999A1 (en) Methods and compositions for the construction and use of fusion libraries using computational protein design methods
AU8542701A (en) Stress proteins and peptides and methods of use thereof
IL162134A0 (en) Human cDNAs and proteins, and uses thereof
AU2002250386A1 (en) Expansin protein and polynucleotides and methods of use
EP1401858A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS COATING THEREOF AND METHOD OF USE
EP1432726A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS CODED FOR THEM, AND METHOD OF USE
AU2003254003A8 (en) Pr/set-domain containing nucleic acids, polypeptides, antibodies and methods of use
EP1532238A4 (en) THERAPEUTIC POLYPEPTIDES, THESE CODING NUCLEIC ACIDS AND METHOD OF USE
EP1539985A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THESE POLYPEPTIDES, AND METHODS OF USE
EP1399537A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THEM, AND METHODS OF USE
AU2002364696A8 (en) Crystalline neutrokine-alpha protein, method of preparation thereof, and method of use thereof
EP1406921A4 (en) HYPOGLYCAEMIC PEPTIDES AND METHOD FOR USE THEREOF

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220820